The Latest Breaking News from Twist Bioscience

The DNA Data Storage Alliance introduced its inaugural specifications for DNA-based data storage this week. This specification outlines a method for encoding essential information within a DNA data archive, crucial for developing and commercializing an interoperable storage ecosystem. DNA data storage uses short strings of deoxyribonucleic acid (DNA) called oligonucleotides…

Cathie Wood's ARK Innovation is on top for the year again — racing back past Fidelity Blue Chip Growth. She can thank this stock.

Shares of the synthetic biology leader have defied gravity. That could change after the next quarterly results are released.

Wall Street hasn't fully digested what currency devaluation really means for biotech stocks.

Twist Bioscience Corporation (NASDAQ:TWST) has entered into a research collaboration and exclusive option license agreement with Astellas Pharma Inc (OTC:ALPMF) to conduct research activities to identify and optimize proprietary Twist antagonist antibodies. The antibodies will target an undisclosed checkpoint inhibitor pathway in the tumor microenvironment as potential therapeutic development candidates.  Ligands in this pathway are…

Twist Bioscience (NASDAQ:TWST) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Twist Bioscience will report an earnings per share (EPS) of $-1.28.

Twist Bioscience Corporation (NASDAQ: TWST) and MediSix Therapeutics have collaborated to discover novel antibodies 

Twist Bioscience Corporation (NASDAQ: TWST) has priced its upsized underwritten public offering of 

Twist Bioscience Corp (NASDAQ: TWST) and Eleven Therapeutics have created a replicon tool that could be used for studying viral genome replication, antiviral drug screening, and vaccine & therapeutic development.